The data, from the SUMMIT and CREST phase II trial cohorts, suggest that the mechanism of bortezomib-induced thrombocytopenia varies from that of other cytotoxic agents and should be managed ...

Bortezomib (a proteasome inhibitor) has recently been approved for treatment of relapsed multiple myeloma, a plasma cell neoplasia, owing to the sensitivity of immunoglobulin-synthesizing myeloma ...